The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 16, 2016
Filed:
Jul. 26, 2012
Celia Dominguez, Los Angeles, CA (US);
Leticia M. Toledo-sherman, Santa Monica, CA (US);
Stephen Martin Courtney, Oxfordshire, GB;
Michael Prime, Oxfordshire, GB;
William Mitchell, Lincolnshire, GB;
Christopher John Brown, Abingdon, GB;
Paula C. DE Aguiar Pena, Oxfordshire, GB;
Peter Johnson, Oxfordshire, GB;
Celia Dominguez, Los Angeles, CA (US);
Leticia M. Toledo-Sherman, Santa Monica, CA (US);
Stephen Martin Courtney, Oxfordshire, GB;
Michael Prime, Oxfordshire, GB;
William Mitchell, Lincolnshire, GB;
Christopher John Brown, Abingdon, GB;
Paula C. De Aguiar Pena, Oxfordshire, GB;
Peter Johnson, Oxfordshire, GB;
CHDI Foundation, Inc., New York, NY (US);
Abstract
Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.